Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

Recommended Reading FDA advisers split vote on GSK kidney disease drug, complicating regulatory path The Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) will present data from the Phase 3 LIBERTY-CUPID Study C evaluating the investigational use ...

Hence, investors should also focus on Dupixent’s performance, sales of which are recorded by Sanofi SNY. Regeneron has a collaboration agreement with Sanofi for drugs like Dupixent and Kevzara.

Within the Sanofi antibody collaboration, LDL cholesterol reduction drug Praluent has seen a slow launch trajectory because of payer restrictions, but we think US sales growth can rebound now that ...

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

The breakthrough came after the investment group provided France with guarantees on maintaining jobs and production in the ...

Sales of Dupixent, Sanofi’s blockbuster eczema drug, rose 23.8% to 3.48 billion euros. Also Read: FDA Approves Regeneron/Sanofi’s Blockbuster Dupixent For Smoker’s Lung Disease New pharma ...